Idiopathic Pulmonary Fibrosis (IPF)
Conditions
Interventions
control group:the placebo of Shenlong granule
Sponsors
The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine Shenyang Liaoning
Eligibility
Sex/Gender
All
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Aged between 40 and 85 years old regardless of gender. (2) Meeting the diagnostic criteria for idiopathic pulmonary fibrosis (IPF) with the syndrome of pulmonary deficiency and collateral stasis. (3) Not having participated in any other interventional trials within one month prior to enrollment. (4) Signing the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Evidence of significant obstructive pulmonary disease. (2) Patients who develop lower respiratory tract infections within 4 weeks prior to the baseline period and/or during the screening period and require treatment with antibiotics or inhaled glucocorticoids or patients who are receiving treatment with pirfenidone or nintedanib. (3) Patients with a history of any malignant tumor at present or any malignant tumor that may lead to death or require major medical or surgical intervention within the next year. (4) Patients in acute exacerbation or in the advanced and critical stage. (5) Patients with other primary pulmonary diseases (such as bronchial asthma chronic obstructive pulmonary disease lung cancer). (6) Patients with severe primary diseases of organs such as the cardiovascular system kidneys and liver. (7) Patients with acute diseases such as bleeding and fever. (8) Pregnant or lactating women or patients with a recent plan to become pregnant. (9) Patients who are known to be allergic to the components of the test drugs. (10) Patients who in the opinion of the researcher should not be included such as those with mental illnesses.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| six-minute walking test (6MWT);The frequency of the acute exacerbation stage of idiopathic pulmonary fibrosis(AE-IPF); | — |
Secondary
| Measure | Time frame |
|---|---|
| Arterial blood gas analysis;lung function;medified Medical Research Council Score;Emergency drug utilization rate;Health-related Quality of Life (HRQoL) Score;The proportion of disease-free survival;lung High-Resolution Computed Tomography Quantitative integration;TCM Syndrome Integral (TCMSS); | — |
Countries
China
Contacts
Public ContactLYU Xiaodong
Liaoning University of Traditional Chinese Medicine
Outcome results
None listed